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Although the major diseases transmitted by transfusion today are AIDS and hepatitis, many
others also are known. These include CMV, syphilis, Chagasdisease, babesiosis, parvovirus B19,
malaria, Epstein-Barr infection, and many others that have been reported only once or twice.
Reducing the risk oftransfusion-transmitted diseases is a problem for donor centers where donor
screening and laboratory testing for possible carriers is undertaken. Physicians should be aware
that thepotential fordisease transmission is always present whentransfusions areadministered.
The long-standing concern about transfusion-transmitted hepatitis and the intense
and, at times almost hysterical, response to the knowledge that HIV infection also is
transfusion-transmitted have overshadowed the fact that still other diseases arespread
by blood component transfusion (Table 1) [1]. With someofthe diseases all recipients
are at risk, and with others only selected groups of recipients are susceptible. Donor
selection, pre-donation questioning, and laboratory testing are the measures used to
identify potentially infectious donors. The burden of such intervention falls on donor
centers and requires relatively little involvement by practicing physicians. Physicians,
however, should not be entirely ignorant of donor screening practices, because the
family doctor is often called upon to advise donor-patients who have been deferred
from donating or in whom some "abnormality" has been found at or after donation.
Of more direct concern to practicing physicians are those cases in which only
selected groups of recipients, usually those who are immunosuppressed, are at risk.
Here physicians must make judgments about the selection of components that will
reduce the risk ofdisease transmission.
The purpose ofthis review is to address sometransfusion-transmitted diseases. HIV
infection and hepatitis, which are discussed elsewhere in this symposium, will not be
covered.
CYTOMEGALOVIRUS (CMV)
CMV infections are a well-known complication oftransfusion and in some groups of
recipients are a major cause of morbidity and mortality. The subject has been well
reviewed by Tegtmeier [2] and by Adler [3].
CMV infection, as measured by seroprevalence studies, occurs in from 50 to 100
percent of U.S. adults. Once infected, individuals harbor the viral genome for long
periods of time and, even though asymptomatic, are infectious. The presence of
347
Abbreviations: CMV: cytomegalovirus STS: serologic test forsyphilis
Address reprint requests to: Joseph R. Bove, M.D., Blood Bank, Yale-New Haven Hospital, 20 York
Street, New Haven, CT06504
Copyright © 1990 by The Yale Journal ofBiology and Medicine, Inc.
All rights ofreproduction in any form reserved.JOSEPH R. BOVE
TABLE 1
Some Infectious Agents That Have Been Transmitted by Blood
Component Transfusion
Viruses













Trypanosoma cruzi (Chagas disease)
Filaria (filariasis)
"Not yetdocumented
circulating antibodies indicates a carrier state that is associated with the ability to
transmit infection.
Uninfected persons are antibody-negative and are at risk of primary infection by
blood component transfusion. Antibody-positive persons are susceptible to reinfection
with a different viral strain or to reactivation of the latent virus they harbor. In most
cases, CMV infection is clinically unimportant, but in some severely immunosup-
pressed individuals transfusion-transmitted CMV has life-threatening potential.
Groups said to be at riskofserious consequences from CMV are listed in Table 2. In
most medical centers, blood components that contain cellular elements are selected or
processed in a way that will reduce or eliminate the risk of CMV transmission before
transfusion into them.
The most common way to provide "CMV-negative" components for patients who
are at risk is by testing the donor unit for antibodies to CMV and issuing only those
components that test negative [4]. Because of the high prevalence of seropositivity in
adult populations, this approach has proven difficult for many blood banks. There is a
report that donors who have only IgM antibodies are the ones most likely to infect
TABLE 2
Suggested Indications for Use ofCMV-Negative Blood Components
1. Newborn infants weighing less than 1,200 grams at birth ifthe mother is CMV-antibody-negative or if
her antibody status is unknown
2. Exchange transfusion in all newborns
3. Intrauterine transfusions
4. Bone marrow transplant recipients
5. Bone marrow transplant candidates who are CMV-antibody-negative or unknown
6. Pregnant women in whom primary infection could pose a risk to the unborn child; does not include
women at or near term or women with CMV antibodies
7. Children with documented congenital immune deficiencies
8. Heart, lung, or heart/lung transplant recipients
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recipients, but this datum is unconfirmed (5]. Washed or frozen-deglycerolized
components seem to be an acceptable alternative, especially for newborns [6]. Recent
reports that third-generation leukocyte filters are also effective are promising, espe-
cially so because of the ever-increasing demand for "CMV-negative" transfusions
[7,8].
SYPHILIS
Transfusion-transmitted syphilis is almost non-existent today, despitetheincrease in
reported primaryand secondary syphilis. Alldonations aretested, using a serologic test
for syphilis (STS), hence only those very few donors who are STS-negative but
spirochetemic poseany risk. Inaddition, thespirochetedoes notsurvivewell at40C, the
temperature at which red blood cell components are stored. For this reason, only red
cell components stored for less than four days or platelets, which are stored at 220C,
can transmit the disease. Occasional cases of transmission from platelets donated by
such individuals have been reported [9].
MALARIA
Although no cases oftransfusion-related malaria have been reported to the Centers
for Disease Control for the most recent two years, the risk of transmission remains.
Worldwide travel and recent immigration patterns from endemic areas make it almost
certain that cases will continue to occur. Because transfusion-transmited malaria is so
infrequent, the correct diagnosis is often delayed. This fact is unfortunate because
early treatment is effective, and delay can be fatal. Serologic testing can detect some
carriers but is not indicated for donor screening. Current regulations do not allow
individuals to donate for three years after they have had malaria, have taken malarial
prophylaxis, or have visited in or immigrated from endemic areas. This screening
approach is generally effective, as evidenced by thevery low incidence ofcases.
CHAGAS DISEASE
Chagas disease is widespread and well-known in the Western hemisphere, especially
in South America, Central America, and Mexico. Perhaps as many as 10-15 million
persons are infected, many ofwhom areessentially asymptomatic. Acute infection can
be fatal, but this result is unusual. Moreoften a chronic carrier state follows infection.
At times it is symptomatic with cardiac and visceral involvement; more often, no
significant symptoms arenoted, but patients became carriers and are infectious.
Transfusion-transmitted Chagas disease has been reported twice in North America
[10,11]. In each case the suspected carrier had emigrated from South or Central
America. Thus, the increasing number ofindividuals from endemic areas who now live
in the U.S. represents a new problem for blood-collecting agencies. There is no good
test for donor screening. Current tests have a false-positive rateof 1-3 percent. Adding
such a test tothedonor-processing routinewill bedifficult, becausesomanydonorswho
are not infected will have to be notified about the positive finding and placed on lists of
deferred donors. In a like manner, to select Hispanics for testing or to defer them
without testing would be socially unacceptable. The Public Health Service is address-
ing this problem, but no easy solution seems forthcoming. One author hascalled for an




Babesiosis has been transmitted by transfusion throughout the world [13,14].
Splenectomized recipients seem to be at increased risk [15], and at least one fatal case
is reported [16]. There is a reservoir of infected individuals, at first thought to be
localized to eastern Long Island and adjacent Connecticut, but now reported in other
areas. One study ofantibody prevalence in the Cape Cod-Boston, Massachusetts, area
found positive results in 3.3-4.9 percent of donors tested [17]. It is not known how
many, if any, of these antibody-positive persons are infectious. There is no consensus
about what, ifanything, should be done to limit the spread oftransfusion-transmitted
babesiosis. Neither additional questioning about tick bites nor geographic restrictions
on summer bloodmobiles seem indicated. Serological testing and/or examination of
blood films from all donors is not practical. No reasonable solution to the problem is
obvious; the fact that it is, at present, a minor problem, suggests that no action will be
forthcoming.
PARVOVIRUS B19 INFECTIONS
Parvovirus B19 has been identified as the etiologic agent of erythema infectiosum
(fifth disease) in children and as a major cause of the transient aplastic crises seen in
patients with hemolytic anemias. It has also been reported to cause severe chronic
anemia, particularly in immunodeficient patients.
Parvovirus B19 seroconversion and infection have been reported after transfusion of
factor VII concentrates [18]. So far, the number of reports is small, but the potential
for increased interest and awareness is present, especially since a test for antibodies to
parvovirus B19 is becoming more readily available. It may be that in the near future it
will be considered appropriate to use parvovirus B19-negative components for selected
patients, in a manner similar to current practice with CMV.
LYME DISEASE
The association of the spirochete Borrelia burgdorferi with Lyme disease has
prompted an interest in whether infected individuals who donate blood could transmit
the infection totheir recipients [19]. Thereare noreported cases todate, but thesetting
for such transmission seems so likely that it should be only a matter of time until the
first case of transfusion-transmitted Lyme disease is reported. The infection is com-
mon, especially during the summer months and especially in the upper northeastern
region ofthe country. There is a period ofspirochetemia during which patients may be
essentially asymptomatic and therefore eligible todonate blood. Theorganism survives
in blood products under the storage conditions generally used, although these experi-
ments were done using relatively large innocula of Borrelia [20]. It only remains for
some astute clinician to suspect Lyme disease and collect the appropriate blood
samples before it is added to the ever-growing list oftransfusion-transmitted diseases.
The American Association ofBlood Banks, in response to the public's interest in this
problem, has issued a statement suggesting that: (1) donor testing is not appropriate,
even in endemic areas; (2) additional questions at the time of blood donation are not
necessary; and (3) neither a tick bite nor a history of Lyme disease with recovery are
cause for donor deferral.
While many other diseases have been transmitted by transfusion, in each case the
number is small and none are a major problem. Transfusion is safer today than it has
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ever been. It will be safer tomorrow than it is today, but it will never be absolutely safe.
The only transfusion that cannot possibly transmit disease is the one not given.
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